Actively Recruiting
Evaluating One vs Two Thermal Ablation Probes for Treating Cervical Precancer in Women Living With HIV in Zimbabwe
Led by Fred Hutchinson Cancer Center · Updated on 2026-11-03
300
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Cervical cancer affects women in low- and middle-income countries, especially women living with HIV WLWH who face a higher risk. This research evaluates whether using two thermal ablation TA probes instead of one improves treatment for cervical precancerous lesions in WLWH. The study aims to support better cervical cancer prevention and contribute to the World Health Organizations goals for eliminating cervical cancer by 2030. Participants will first be screened using HPV testing or visual assessment. Those with positive results undergo exams including biopsies and imaging to assess eligibility. Eligible women with a type 1 transformation zone will receive TA treatment with either one or two probes, randomly assigned. Follow-up occurs at 6 months with HPV tests, biopsies, and visual exams. Women not eligible for TA will be referred for local care. During the study, participants will undergo clinical exams, digital imaging, and brush biopsies at enrollment and at 6 months. Researchers will measure the proportion of participants with persistent HPV at 6 months to assess treatment outcomes. The study monitors safety, acceptability, and feasibility of the two-probe method over the course of the trial, ending in May 2028.
CONDITIONS
Brief Title
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS7 Zimbabwe
Research Team
A
Araceli Loera, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here